

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-16. (canceled)

17. (currently amended) A factor VIII/von Willebrand Factor complex (factor VIII/vWF-complex)~~vWF-complex particularly~~ containing high-molecular weight vWF multimers, ~~obtainable from a factor VIII/vWF-containing solution by cation exchange chromatography~~ and free from low-molecular weight vWF multimers.

18. (currently amended) The factor VIII/vWF-complex of Claim 17, wherein said factor VIII/vWF-complex is ~~particularly free from low-molecular vWF multimers, inactive vWF degradation products, products and non-complexed factor VIII factor VIII free from platelet agglutinating vWF activity and factor VIIIa activity.~~

19. (currently amended) A factor VIII/von Willebrand Factor complex (factor VIII/vWF-complex) ~~The factor VIII/vWF-complex of Claim 18, wherein said factor VIII/vWF-complex~~ has a specific vWF activity of at least 66 U/mg protein and a specific factor VIII activity of at least 500 U/mg protein.

20. (currently amended) A preparation comprising the factor VIII/vWF-complex of Claim 19, wherein said preparation is virus-safe and free from infectious material.

21. (previously presented) The preparation of Claim 20, wherein said preparation is present in storage-stable form.

22. (previously presented) The preparation of Claim 20, wherein said preparation is formulated as a pharmaceutical preparation.

23. (new) The factor VIII/vWF complex of Claim 19, wherein said factor VIII/vWF-complex has a specific vWF activity of between 66-83 U/mg protein.

24. (new) A purified factor VIII/von Willebrand Factor complex (factor VIII/vWF-complex) obtained by

(a) adsorbing a plurality of factor VIII/vWF complexes to a cation exchanger, wherein the plurality of factor VIII/vWF complexes comprises factor VIII/vWF complexes containing low-molecular weight vWF multimers and factor VIII/vWF complexes containing high-molecular weight vWF multimers;

(b) eluting the plurality of factor VIII/vWF complexes from the cation exchanger by a step-wise elution process, whereby complexes containing low-molecular weight vWF multimers are preferentially eluted in one step of the process and complexes containing high-molecular weight vWF multimers are preferentially eluted in another step of the process; and

(c) collecting at least some of the complexes containing high-molecular weight vWF multimers to obtain the purified factor VIII/vWF-complex.

25. (new) The factor VIII/vWF-complex of claim 24 that is obtained by eluting factor VIII/vWF complexes containing low-molecular weight vWF multimers from the cation exchanger at a salt concentration ≥ 250 mM and ≤ 300 mM, and eluting factor VIII/vWF complexes containing high-molecular weight vWF multimers from the cation exchanger at a salt concentration ≥ 300 mM.

26. (new) The factor VIII/vWF-complex of claim 25 that is obtained by adsorbing the plurality of factor VIII/vWF complexes to the cation exchanger at a salt concentration of ≤ 250 mM salt and eluting factor VIII/vWF complexes containing high-molecular weight vWF multimers from the cation exchanger at a salt concentration ≥ 350 mM.

27. (new) A preparation comprising the factor VIII/vWF-complex of Claim 17, wherein said preparation is virus-safe and free from infectious material.

28. (new) A preparation comprising the factor VIII/vWF-complex of Claim 24, wherein said preparation is virus-safe and free from infectious material.